In a report released today, Gil Blum from Needham reiterated a Buy rating on Taysha Gene Therapies, with a price target of $10.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gil Blum has given his Buy rating due to a combination of factors that indicate a positive outlook for Taysha Gene Therapies. The FDA’s feedback on the design of the registrational study for TSHA-102 in Rett syndrome has been seen as reducing risk. The study design includes a manageable enrollment of 15 patients, with a significant milestone improvement expected in a third of them, which aligns with previous Phase I study results where 83% of patients showed improvement.
Furthermore, the FDA has granted TSHA-102 a breakthrough designation, reflecting the agency’s confidence in the clinical data’s robustness. This designation is in line with the FDA’s recent guidance aimed at expediting product development timelines. These factors collectively enhance the prospects for TSHA-102, positioning it favorably compared to competitors and justifying the Buy rating with an increased target price of $10.
According to TipRanks, Blum is an analyst with an average return of -2.2% and a 37.10% success rate. Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Recursion Pharmaceuticals, and I-MAB.
In another report released on September 22, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $13.00 price target.